Advances in understanding of colorectal liver metastasis and implications for the clinic

References

• Ferlay J, Parkin D, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46(4):765-81
   PubMed Web of Science ®Google Scholar
• van der Pool A, Damhuis RA, Ijzermans JN, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population based series. Colorectal Dis 2012;14(1):56-61
   PubMed Web of Science ®Google Scholar
• Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992–2008. Cancer Epidemiol Biomarkers Prev 2012;21(3):411-16
   PubMed Web of Science ®Google Scholar
• Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-36
   PubMed Web of Science ®Google Scholar
• Robinson S, Manas DM, Pedley I, et al. Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol 2011;20(2):57-72
   PubMed Web of Science ®Google Scholar
• Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27(22):3677-83
   PubMed Web of Science ®Google Scholar
• Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230(3):309
   PubMed Web of Science ®Google Scholar
• Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7(1):109-17
   PubMed Web of Science ®Google Scholar
• Slesser A, Georgiou P, Brown G, et al. The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis 2013;30(4):457-70
   PubMed Web of Science ®Google Scholar
• Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol 2013;6(5):381-95
   PubMed Web of Science ®Google Scholar
• Pantaleo M, Astolfi A, Nannini M, et al. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 2008;99(10):1729-34
   PubMed Web of Science ®Google Scholar
• De Jong KP, Stellema R, Karrenbeld A, et al. Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998;28(4):971-9
   PubMed Web of Science ®Google Scholar
• van der Wal GE, Gouw AS, Kamps JA, et al. Angiogenesis in synchronous and metachronous colorectal liver metastases: the liver as a permissive soil. Ann Surg 2012;255(1):86-94
   PubMed Web of Science ®Google Scholar
• Neal C, Garcea G, Doucas H, et al. Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer 2006;42(12):1728-43
   PubMed Web of Science ®Google Scholar
• Lugli A, Zlobec I. Gene signatures in colorectal cancer, in diagnostic, prognostic and therapeutic value of gene signatures. Springer; NY, USA: 2012. p. 115-36
   Google Scholar
• Miyagawa S, Soeda J, Takagi S, et al. Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum Pathol 2004;35(11):1392-6
   PubMed Web of Science ®Google Scholar
• Konishi K, Watanabe Y, Shen L, et al. DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS One 2011;6(11):e27889
   PubMed Web of Science ®Google Scholar
• Ono M, Sakamoto M, Ino Y, et al. Cancer cell morphology at the invasive front and expression of cell adhesion‐related carbohydrate in the primary lesion of patients with colorectal carcinoma with liver metastasis. Cancer 1996;78(6):1179-86
   PubMed Web of Science ®Google Scholar
• Ghadjar P, Rubie C, Aebersold DM, et al. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 2009;125(4):741-5
   PubMed Web of Science ®Google Scholar
• Ayaki M, Komatsu K, Mukai M, et al. Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas. Clin Cancer Res 2001;7(10):3106-12
   PubMed Web of Science ®Google Scholar
• Sun X, Cheng G, Hao M, et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 2010;29(4):709-22
   PubMed Web of Science ®Google Scholar
• Wang SC, Lin JK, Wang HS, et al. Nuclear expression of CXCR4 is associated with advanced colorectal cancer. Int J Colorectal Dis 2010;25(10):1185-91
   PubMed Web of Science ®Google Scholar
• Wu Y, Jin M, Xu H, et al. Clinicopathologic significance of HIF-1, CXCR4, and VEGF expression in colon cancer. Clin Dev Immunol 2010;2010: pii 537531
   PubMedGoogle Scholar
• Li JQ, Miki H, Wu F, et al. Cyclin a correlates with carcinogenesis and metastasis, and p27 correlates with lymphatic invasion, in colorectal neoplasms. Hum Pathol 2002;33(10):1006-15
   PubMed Web of Science ®Google Scholar
• Charnsangavej C, Clary B, Fong Y, et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol 2006;13(10):1261-8
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29(6):610-18
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71(4):1263-71
   PubMed Web of Science ®Google Scholar
• Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353(25):2654-66
   PubMed Web of Science ®Google Scholar
• Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132(7):2328-39
   PubMed Web of Science ®Google Scholar
• Sasaki A, Tanaka F, Mimori K, et al. Prognostic value of tumor-infiltrating FOXP3 regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol 2008;34(2):173-9
   PubMed Web of Science ®Google Scholar
• Katz SC, Pillarisetty V, Bamboat ZM, et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol 2009;16(9):2524-30
   PubMed Web of Science ®Google Scholar
• Katz SC, Bamboat ZM, Maker AV, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 2013;20(3):946-55
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117(6):1466-76
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang CJ, Restifo PN. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909-15
   PubMed Web of Science ®Google Scholar
• Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis 1. Radiology 2002;224(3):748-56
   PubMed Web of Science ®Google Scholar
• Sahani DV, Bajwa MA, Andrabi Y, et al. Current status of imaging and emerging techniques to evaluate liver metastases from colorectal carcinoma. Ann Surg 2014;259(5):861-72
   PubMed Web of Science ®Google Scholar
• Kane RA, Hughes LA, Cua EJ, et al. The impact of intraoperative ultrasonography on surgery for liver neoplasms. J Ultrasound Med 1994;13(1):1-6
   PubMed Web of Science ®Google Scholar
• Solomon MJ, Stephen MS, Gallinger S, et al. Does intraoperative hepatic ultrasonography change surgical decision making during liver resection? Am J Surg 1994;168(4):307-10
   PubMed Web of Science ®Google Scholar
• Sahani DV, Kalva SP, Tanabe KK, et al. Intraoperative US in patients undergoing surgery for liver neoplasms: comparison with MR imaging 1. Radiology 2004;232(3):810-14
   PubMed Web of Science ®Google Scholar
• Lordan JT, Stenson MK, Karanjia DN. The value of intraoperative ultrasound and preoperative imaging, individually and in combination, in liver resection for metastatic colorectal cancer. Ann R Coll Surg Engl 2011;93(3):246
   PubMed Web of Science ®Google Scholar
• Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010;257(3):674-84
   PubMed Web of Science ®Google Scholar
• Smith TJ, Korngold E, Orloff LS. Preoperative imaging in colorectal liver metastases: current practices. Curr Surg Rep 2014;2(2):1-9
   Google Scholar
• Fowler KJ, Linehan CD, Menias OC. Colorectal liver metastases: state of the art imaging. Ann Surg Oncol 2013;20(4):1185-93
   PubMed Web of Science ®Google Scholar
• Bhattacharjya S, Bhattacharjya T, Baber S, et al. Prospective study of contrast‐enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 2004;91(10):1361-9
   PubMed Web of Science ®Google Scholar
• Kamel IR, Choti MA, Horton KM, et al. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology 2003;227(3):752-7
   PubMed Web of Science ®Google Scholar
• Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 2005;5(Spec No A):S149
   PubMedGoogle Scholar
• Sahani DV, Krishnamurthy SK, Kalva S, et al. Multidetector-row computed tomography angiography for planning intra-arterial chemotherapy pump placement in patients with colorectal metastases to the liver. J Comput Assist Tomogr 2004;28(4):478-84
   PubMed Web of Science ®Google Scholar
• Wiering B, Ruers TJ, Krabbe PF, et al. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007;14(2):818-26
   PubMed Web of Science ®Google Scholar
• Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol 2006;24(24):3939-45
   PubMed Web of Science ®Google Scholar
• Maas M, Rutten IJ, Nelemans PJ, et al. What is the most accurate whole-body imaging modality for assessment of local and distant recurrent disease in colorectal cancer? A meta-analysis. Eur J Nucl Med Mol Imaging 2011;38(8):1560-71
   PubMed Web of Science ®Google Scholar
• Tan MC, Linehan DC, Hawkins WG, et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007;11(9):1112-19
   PubMed Web of Science ®Google Scholar
• Fong Y, Saldinger PF, Akhurst T, et al. Utility of F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999;178(4):282-7
   PubMed Web of Science ®Google Scholar
• Holalkere NS, Sahani DV, Blake MA, et al. Characterization of small liver lesions: added role of MR after MDCT. J Comput Assist Tomogr 2006;30(4):591-6
   PubMed Web of Science ®Google Scholar
• Bischof D, Clary BM, Maithel SK, et al. Surgical management of disappearing colorectal liver metastases. Br J Surg 2013;100(11):1414-20
   PubMed Web of Science ®Google Scholar
• Berger-Kulemann V, Schima W, Baroud S, et al. Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg Oncol 2012;38(8):670-6
   PubMed Web of Science ®Google Scholar
• van Kessel CS, Buckens CF, van den Bosch MA, et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 2012;19(9):2805-13
   PubMed Web of Science ®Google Scholar
• Corona-Villalobos CP, Kamel RI. Functional volumetric MRI in assessing treatment response to intra-arterial therapy of primary and secondary liver tumors. J Comput Assist Tomogr 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. Am J Roentgenol 2007;188(4):1001-8
   PubMed Web of Science ®Google Scholar
• Scurr ED, Collins DJ, Temple L, et al. Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations. Br J Radiol 2012;85(1011):225-30
   PubMed Web of Science ®Google Scholar
• Tzeng CWD, Aloia AT. Colorectal liver metastases. J Gastrointest Surg 2013;17(1):195-202
   PubMed Web of Science ®Google Scholar
• Zacharia TT, Saini S, Halpern EF, et al. CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure. Am J Roentgenol 2006;186(4):1067-70
   PubMed Web of Science ®Google Scholar
• Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302(21):2338-44
   PubMed Web of Science ®Google Scholar
• Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 2012;30(36):4566-72
   PubMed Web of Science ®Google Scholar
• Capussotti L, Vigano’ L, Ferrero A, et al. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 2007;14(3):1143-50
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240(4):644-57
   PubMed Web of Science ®Google Scholar
• Quan D, Gallinger S, Nhan C, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery 2012;151(6):860-70
   PubMed Web of Science ®Google Scholar
• Page AJ, Kooby AD. Perioperative management of hepatic resection. J Gastrointest Oncol 2012;3(1):19-27
   PubMedGoogle Scholar
• Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg 2010;210(6):934-41
   PubMed Web of Science ®Google Scholar
• Mentha G, Majno PE, Andres A, et al. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006;93(7):872-8
   PubMed Web of Science ®Google Scholar
• Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27(20):3379-84
   PubMed Web of Science ®Google Scholar
• Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 2003;197(2):233-41
   PubMed Web of Science ®Google Scholar
• Mayo SC, Pulitano C, Marques H, et al. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg 2013;216(4):707-16
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013;14(12):1208-15
   PubMed Web of Science ®Google Scholar
• Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235(6):759
   PubMed Web of Science ®Google Scholar
• Tsai MS, Su YH, Ho MC, et al. Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007;14(2):786-94
   PubMed Web of Science ®Google Scholar
• Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343(8910):1405-10
   PubMed Web of Science ®Google Scholar
• Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012;255(3):405-14
   PubMed Web of Science ®Google Scholar
• Knoefel W, Gabor I, Rehders A, et al. In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two‐stage liver resection. Br J Surg 2013;100(3):388-94
   PubMed Web of Science ®Google Scholar
• de Santibañes E, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the “ALPPS” approach. Ann Surg 2012;255(3):415-17
   PubMed Web of Science ®Google Scholar
• Chun YS, Laurent A, Maru D, et al. Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 2009;10(3):278-86
   PubMed Web of Science ®Google Scholar
• Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356(15):1545-59
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239(6):818
   PubMed Web of Science ®Google Scholar
• Arita J, Ono Y, Takahashi M, et al. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Ann Surg Oncol 2014;21(Suppl 3):S390-7
   PubMedGoogle Scholar
• Shindoh J, Tzeng CW, Aloia TA, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 2013;20(8):2493-500
   PubMed Web of Science ®Google Scholar
• Ribero D, Abdalla EK, Madoff DC, et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007;94(11):1386-94
   PubMed Web of Science ®Google Scholar
• Shindoh J, Truty MJ, Aloia TA, et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 2013;216(2):201-9
   PubMed Web of Science ®Google Scholar
• Shindoh J, Vauthey JN, Zimmitti G, et al. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg 2013;217(1):126-33
   PubMed Web of Science ®Google Scholar
• Haddad AJ, Bani Hani M, Pawlik TM, Cunningham SC. Colorectal liver metastases. Int J Surg Oncol 2011;2011:285840
   PubMedGoogle Scholar
• Tsai S, Marques HP, de Jong MC, et al. Two‐stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) 2010;12(4):262-9
   PubMed Web of Science ®Google Scholar
• Schadde E, Ardiles V, Slankamenac K, et al. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. World J Surg 2014;38(6):1510-19
   PubMed Web of Science ®Google Scholar
• de Jong MC, Mayo SC, Pulitano C, et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009;13(12):2141-51
   PubMed Web of Science ®Google Scholar
• Kelly C, Cassidy J. Chemotherapy in metastatic colorectal cancer. Surg Oncol 2007;16(1):65-70
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil–leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18(1):136-6
   PubMed Web of Science ®Google Scholar
• Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22(11):2084-91
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26(12):2013-19
   PubMed Web of Science ®Google Scholar
• Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360(6):563-72
   PubMed Web of Science ®Google Scholar
• Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg 2013;216(1):41-9
   PubMed Web of Science ®Google Scholar
• Loupakis F, Schirripa M, Caparello C, et al. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013;108(12):2549-56
   PubMed Web of Science ®Google Scholar
• Zorzi D, Laurent A, Pawlik TM, et al. Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007;94(3):274-86
   PubMed Web of Science ®Google Scholar
• Morris-Stiff G, Tan YM, Vauthey J. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 2008;34(6):609-14
   PubMed Web of Science ®Google Scholar
• Robinson SM, Wilson CH, Burt AD, et al. Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 2012;19(13):4287-99
   PubMed Web of Science ®Google Scholar
• Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007;246(4):559-67
   PubMed Web of Science ®Google Scholar
• Mulier S, Miao Y, Mulier P, et al. Electrodes and multiple electrode systems for radiofrequency ablation: a proposal for updated terminology. Eur Radiol 2005;15(4):798-808
   PubMed Web of Science ®Google Scholar
• Rocha FG, D’Angelica M. Treatment of liver colorectal metastases: role of laparoscopy, radiofrequency ablation, and microwave coagulation. J Surg Oncol 2010;102(8):968-74
   PubMed Web of Science ®Google Scholar
• Stang A, Fischbach R, Teichmann W, et al. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009;45(10):1748-56
   PubMed Web of Science ®Google Scholar
• Hompes D, Prevoo W, Ruers T. Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. Cancer imaging 2010;11:23-30
   Web of Science ®Google Scholar
• Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242(2):158-71
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Bauer TW, Chun YS, et al. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford) 2013;15(2):119-30
   PubMed Web of Science ®Google Scholar
• Malik U, Mohiuddin M; Elsevier. External-beam radiotherapy in the management of liver metastases. Semin Oncol 2002;29(2):196-201
   PubMed Web of Science ®Google Scholar
• Dawood O, Mahadevan A, Goodman KA. Stereotactic body radiation therapy for liver metastases. Eur J Cancer 2009;45(17):2947-59
   PubMed Web of Science ®Google Scholar
• van der Pool AE, Méndez Romero A, Wunderink W, et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010;97(3):377-82
   PubMed Web of Science ®Google Scholar
• Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 2005;23(34):8739-47
   PubMed Web of Science ®Google Scholar
• Rusthoven CG, Christine F. Lauro, Brian D, Kavanagh, Tracey E, Schefter; Elsevier. Stereotactic body radiation therapy (SBRT) for liver metastases: a clinical review. Semin Colon Rectal Surg 2014;25:1-48-52
   Google Scholar
• Lewandowski RJ, Thurston KG, Goin JE, et al. Y90 microsphere (therasphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135–150 Gy as measured by [18F] fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005;16(12):1641-51
   PubMed Web of Science ®Google Scholar
• Bester L. Baerbel Meteling, David Boshell, Akshat Saxena, David L Morris. Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer. Hepatic Oncol 2014;1(2):215-28
   PubMedGoogle Scholar
• Benson AB3rd, Geschwind JF, Mulcahy MF, et al. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study. Eur J Cancer 2013;49(15):3122-30
   PubMed Web of Science ®Google Scholar
• Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12(12):1711-20
   PubMed Web of Science ®Google Scholar
• Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010;103(3):324-31
   PubMed Web of Science ®Google Scholar
• Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247(6):1029-35
   PubMed Web of Science ®Google Scholar
• Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012;83(3):887-94
   PubMed Web of Science ®Google Scholar
• Lucke B, Breedis C, Woo Zp, et al. Differential growth of blood-borne metastatic tumors in liver and lung (experiments with rabbit V-2 carcinoma). Am J Pathol 1950;27(4):729-30
   Web of Science ®Google Scholar
• Harada T, Matsuo K, Inoue T, et al. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996;224(1):4
   PubMed Web of Science ®Google Scholar
• Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103(4):914-21
   PubMed Web of Science ®Google Scholar
• Page AJ, Cosgrove DC, Philosophe B, et al. Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am 2014;23(2):289-311
   PubMed Web of Science ®Google Scholar
• Martin RC, Joshi J, Robbins K, et al. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009;2009:539795
   PubMedGoogle Scholar
• Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 2011;18(1):192-8
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012;32(4):1387-95
   PubMed Web of Science ®Google Scholar
• Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol 2013;24(8):1209-17
   PubMed Web of Science ®Google Scholar
• Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38(11 Part 1):3784-92
   PubMed Web of Science ®Google Scholar
• Ensminger W, Niederhuber J, Dakhil S, et al. Totally implanted drug delivery system for hepatic arterial chemotherapy. Cancer Treat Rep 1980;65(5-6):393-400
   Google Scholar
• Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003;361(9355):368-73
   PubMed Web of Science ®Google Scholar
• Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7(11):1646-54
   PubMed Web of Science ®Google Scholar
• Stagg RJ, Venook AP, Chase JL, et al. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991;83(6):423-8
   PubMed Web of Science ®Google Scholar
• Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005;23(22):4881-7
   PubMed Web of Science ®Google Scholar
• Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008;15(1):219-26
   PubMed Web of Science ®Google Scholar
• Gluck WL, Akwari OE, Kelvin FM, et al. A reversible enteropathy complicating continuous hepatic artery infusion chemotherapy with 5‐fluoro‐2‐deoxyuridine. Cancer 1985;56(10):2424-7
   PubMed Web of Science ®Google Scholar
• Kemeny N, Daly J, Oderman P, et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984;2(6):595-600
   PubMed Web of Science ®Google Scholar
• Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206(6):685
   PubMed Web of Science ®Google Scholar
• Lorenz M, Müller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;18(2):243-3
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24(9):1395-403
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pasquali S, Nitti DFH. Versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009;3
   Google Scholar
• van Vledder MG, de Jong MC, Pawlik TM, et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 2010;14(11):1691-700
   PubMed Web of Science ®Google Scholar
• Adam R, de Haas RJ, Wicherts DA, et al. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery? Ann Surg 2011;253(2):349-59
   PubMed Web of Science ®Google Scholar
• Pulitanò C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol 2011;18(5):1380-8
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist 2008;13(1):51-64
   PubMed Web of Science ®Google Scholar
• Ekberg H, Tranberg KG, Andersson R, et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986;73(9):727-31
   PubMed Web of Science ®Google Scholar
• Adson MA, van Heerden JA, Adson MH, et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984;119(6):647-51
   PubMed Web of Science ®Google Scholar
• Hughes K, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986;100(2):278-84
   PubMed Web of Science ®Google Scholar
• Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007;14(11):3188-94
   PubMed Web of Science ®Google Scholar
• Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010;116(6):1502-9
   PubMed Web of Science ®Google Scholar